Tudor Investment Corp Et Al boosted its holdings in Allakos Inc. (NASDAQ:ALLK – Get Rating) by 15.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,411 shares of the company’s stock after acquiring an additional 4,424 shares during the quarter. Tudor Investment Corp Et Al’s holdings in Allakos were worth $198,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Silverarc Capital Management LLC acquired a new stake in Allakos during the 3rd quarter worth about $2,448,000. Cubist Systematic Strategies LLC raised its holdings in Allakos by 146.7% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 262,098 shares of the company’s stock worth $1,604,000 after buying an additional 155,853 shares during the period. Clearline Capital LP raised its holdings in Allakos by 3.7% during the 2nd quarter. Clearline Capital LP now owns 558,888 shares of the company’s stock worth $1,749,000 after buying an additional 19,793 shares during the period. Belvedere Trading LLC acquired a new stake in Allakos during the 3rd quarter worth about $150,000. Finally, Sei Investments Co. acquired a new stake in Allakos during the 2nd quarter worth about $46,000. 93.07% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
ALLK has been the topic of several research analyst reports. Piper Jaffray Companies initiated coverage on Allakos in a research note on Tuesday. They set an “overweight” rating and a $22.00 target price on the stock. Piper Sandler initiated coverage on Allakos in a research note on Tuesday. They set an “overweight” rating and a $22.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Allakos in a research note on Tuesday. Finally, Morgan Stanley lifted their target price on Allakos from $6.00 to $8.00 and gave the company an “equal weight” rating in a research note on Friday, January 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Allakos presently has an average rating of “Hold” and a consensus price target of $14.75.
Allakos Stock Performance
Allakos (NASDAQ:ALLK – Get Rating) last announced its quarterly earnings results on Monday, March 6th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). On average, analysts predict that Allakos Inc. will post -2.23 EPS for the current year.
Allakos Company Profile
Allakos, Inc engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.
- Get a free copy of the StockNews.com research report on Allakos (ALLK)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
Want to see what other hedge funds are holding ALLK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allakos Inc. (NASDAQ:ALLK – Get Rating).
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.